Shanghai Henlius Biotech (HKG:2696) dosed the first patient in international multicenter phase 1 clinical study of Ipilimumab biosimilar HLX13 in mainland China, a Tuesday Hong Kong bourse filing said.
The drug is for the first-line treatment of patients with unresectable hepatocellular carcinoma.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.